|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 利拉鲁肽与格列美脲在单药治疗2型糖尿病中的比较(LEAD-3 Mono):一项随机、双盲、平行分组、52周的Ⅲ期临床试验显示文摘背景 2型糖尿病新的治疗策略,需要针对胰岛素-葡萄糖的相互作用,且同时要降低体重增加和发生低血糖的风险。本文作者旨在调查利拉鲁肽单药治疗2型糖尿病的安全性与有效性。
方法 采用双盲、双模拟、治疗一对照、平行分组的研究,746例早期2型糖尿病患者被随机分配到1次/d利拉鲁肽组[1.2mg(n=251)或1.8mg(n=247)]或格列美脲8mg组(n=248),分别治疗52周。主要结局指标为糖化血红蛋白(HbA1c)的改变程度。采用意向性治疗进行分析。该试验在ClinicalTrials.gov网站的注册编码为NTC00294723.
结果52周时,格列美脲组HbA,。下降了0.51%(s=1.20),而利拉鲁肽1.2mg组下降了0.84%(s=1.23)(差值为-0.33.95%CI-0.53~-0.13;P=0.0014),利拉鲁肽1.8mg组下降了1.14%(S=1.24)(差值为-062,95%CI-0.83—-0.42;P〈0.0001)。利拉鲁肽1.2mg组和1.8mg组各有5例和1例患者因呕吐停止治疗,而格列美脲组未出现这种情况。
结论 利拉鲁肽作为2型糖尿病的初始治疗药物安全有效,与格列美脲相比更能降低HbA1c以及体重、血压和低血糖的发生率。 | Alan Garber Robert Henry Robert Rather Pedro A Garcia-Hernandez Hiromi Rodriguez-Pattzi Israel Olvero-Alvarez Paula M Hale, Milan Zdravkovic Bruce Bode 邓斌(译) | 2009 | 世界临床医学2009，，6： | 5 |
| 2 | Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial显示文摘 | Alan Garber Robert Henry Robert Ratner Pedro A Garcia-Hernandez Hiromi Rodriguez-Pattzi Israel Olvera-Alvarez Paula M Hale Milan Zdravkovic Bruce Bode | 2009 | The Lancet2009，，9662： | 2 |
| 3 | Characterization of conditions for the primary culture of human small intestinal epithelial cells显示文摘 | ALDHOUS M C SHMAKOV A N BODES J | 2001 | Clin Exp Immunol2001，125，1： | 1 |
| 4 | Correction of the bleeding time with lyophilized platelet infusions in dogs on cardiopulmonary bypass 显示文摘 | BODE A P LUST R M READ M S | 2008 | Clin Appl Thromb Hemost2008，14，： | 1 |
| 5 | E 6 ]- Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase 显示文摘 | JEONG C H BODE A M PUGLIESE A | 2009 | Cancer Res2009，69，13： | 1 |
| 6 | Characterization of conditions for the primary culture of human small intestinal epithelial cells显示文摘 | ALDHOUS M C SHMAKOV A N BODE J | 2001 | Clin Exp Immunol2001，125，1： | 1 |
| 7 | An overview of the municipal waste incineration industry in Asia and the former Soviet Union显示文摘 | TIMOTHY R CROCKETT BODE M A | 1996 | Journal of Hazardous Material1996，47，： | 1 |
| 8 | The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects 显示文摘 | BODE A M DONG Z G | 2002 | Cri Rev Oncol Hematol2002，42，1： | 1 |
| 9 | Structure and biosynthesis of mutolide, a novel macrolide from a UV mutant of the fungus F -24 ' 707显示文摘 | Bode H B Walker M Zeeck A | 2000 | Eur J Org Chem2000，，8： | 1 |
| 10 | Characterization of conditions for the primary culture of human small intestinal epithelial cells 显示文摘 | Shmakov A N Bode J | 2001 | Clin Exp Immunol2001，125，1： | 1 |
| 11 | Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial 显示文摘 | Seirica B M Morrow D A Bode C etal | 2010 | Eur Heart J2010，31，16： | 1 |
| 12 | Maillard reaction products as encapsulants for fish oil powders显示文摘 | Augustin M A Sanguansri L Bode 0 | 2006 | Journal of Food Science2006，71，2： | 1 |
| 13 | Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size显示文摘 | Regar E Serruys PW Bode C Holubarsch C Guermonprez JL Wijns W Bartorelli A Constantini C Degertekin M Tanabe K Disco C Wuelfert E Morice MC RAVEL Study Group | 2002 | Circulation2002，106，15： | 1 |
| 14 | Band-gap engineering in Cu(In,Ga)Se2 thin films grown from (In,Ga)2Se3 precursors显示文摘 | Gabor A M Tuttle J R Bode M H | 1996 | Sol Energy Mater & Sol Cells1996，4142，： | 1 |
| 15 | Resveratrol-induced activa- tion of p53 and apoptosis ismediated by extracellular-signal-regula- ted protein kinases and p38 kinase 显示文摘 | She Q B Bode A M Ma W Y | 2001 | Cancer Res2001，61，4： | 1 |
| 16 | Asym- metrical dimethylarginine - - more sensitive than NT - pmBNP to diagnose heart failure in adults with congenital heart disease 显示文摘 | TUTAREL O DENECKE A BODE BOGER S M | 2012 | PLoS One2012，7，33： | 1 |
| 17 | Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plas- minogen activator in baboons 显示文摘 | Runge M S Harker L A Bode C | 1996 | Circulation1996，94，6： | 1 |
| 18 | 查看详情显示文摘 | D Golla S Knoke W Schone G Ernst M Bode A Tunnermann H Welling | | 0，，： | 1 |
| 19 | Crystal structures of the membrane-binding C2 domain of human coagulation factor Ⅴ显示文摘 | Macedo-Ribeiro S Bode W Huber R Quinn-Allen M A Kim S W Ortel T L Bourenkov G P Bartunik H D Stubbs M T Kane W H Fuentes-Prior P | | 0，，： | 1 |
| 20 | The ornithodorin-thrombin crystal structure, a key to the TAP enigma显示文摘 | Stubbs M T Bode W | 1996 | EMBOJ1996，15，22： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员